A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This exploratory, randomized, double-blind, placebo-controlled, multicenter, proof of
concept, Phase 2a study will evaluate the efficacy, safety, tolerability, and
pharmacokinetics (PK) of orally administered GLPG2737, for a treatment period of 52 weeks, in
participants with rapidly progressing ADPKD.